Ying Lin

13PUBLICATIONS

103CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyHaematological tumoursMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|May 21, 2026

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.

|Jan 23, 2026

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Hong-Fei Gao, Guo-Lin Ye, Ying Lin

|Jan 02, 2025

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Ruo-Xi Hong, Fei Xu, Wen Xia

|Jun 25, 2024

A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.

Teng Zhu, Yu-Hong Huang, Wei Li

|Mar 20, 2024

A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer.

Mengmeng Zhang, Kaiwen Zhou, Zilin Wang

|Jan 08, 2024

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Zefei Jiang, Quchang Ouyang, Tao Sun

Pageof 3

Frequent Collaborators

Shusen Wang

Jianping Guo

Yiding Chen

Jianyun Nie

Kun Wang

Qianjun Chen

Zhongyu Yuan

Zefei Jiang

Wei Xie

Yunfang Yu

Frequent Collaborators

Shusen Wang

Jianping Guo

Yiding Chen

Jianyun Nie